Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 26;9(12):3828.
doi: 10.3390/jcm9123828.

Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension

Esam H Alhamad  1 , Joseph G Cal  1 , Nuha N Alrajhi  1 , Waleed M Alharbi  2
Affiliations

Predictors of Mortality in Patients with Interstitial Lung Disease-Associated Pulmonary Hypertension

Esam H Alhamad et al. J Clin Med. .

Abstract

Background: Pulmonary hypertension (PH) is a well-established complication in interstitial lung disease (ILD) patients. The aim of this study is to investigate the physiological and hemodynamic parameters that predict mortality in patients with ILD-PH.

Methods: Consecutive ILD patients who underwent right heart catheterization (n = 340) were included. The information analyzed included demographics and physiological and hemodynamic parameters. Cox regression models were used to identify independent predictors of survival.

Results: In total, 96 patients had PH and an additional 56 patients had severe PH. The overall survival of idiopathic pulmonary fibrosis (IPF) patients with PH was significantly worse than the survival of patients with other types of ILD with PH (p < 0.0001 by log-rank analysis). Patients with a reduced diffusing capacity of the lung for carbon monoxide (DLco) (<35% predicted), six-minute walk test final oxygen saturation by pulse oximetry (SpO2) <88% and pulmonary vascular resistance ≥4.5 Wood units in the ILD-PH cohort had significantly worse survival. IPF diagnosis, forced vital capacity, DLco, systolic pulmonary artery pressure and cardiac index were identified as independent predictors of survival among the ILD-PH cohort.

Conclusions: Patients with ILD-PH have poor prognosis. Physiological and hemodynamic parameters were important factors independently associated with outcome.

Keywords: idiopathic pulmonary fibrosis; interstitial lung disease; pulmonary hypertension; pulmonary vascular resistance; six-minute walk test; survival.

PubMed Disclaimer

Conflict of interest statement

None of the authors have conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Kaplan–Meier survival estimates for the relationship with (A) interstitial lung disease (ILD) patients with and without pulmonary hypertension (PH), (B) idiopathic pulmonary fibrosis (IPF) patients with and without PH, (C) connective tissue disease (CTD) associated ILD patients with and without PH and (D) sarcoidosis patients with and without PH.
Figure 2
Figure 2
Kaplan–Meier survival estimates for interstitial lung disease (ILD) patients with pulmonary hypertension according to the underlying disease idiopathic pulmonary fibrosis (IPF) (red line), connective tissue disease (CTD) associated ILD (green line) and sarcoidosis (blue line).
Figure 3
Figure 3
Kaplan–Meier survival estimates for the relationship with (A) diffusion capacity of the lung for carbon monoxide (DLco) at a threshold of 35% predicted, (B) six-minute walk test (6MWT) final oxygen saturation by pulse oximetry (SpO2) at a threshold of 88%, (C) pulmonary vascular resistance (PVR) ≥ 4.5 Wood units (WU) and (D) 6 min walk distance (6MWD) at a threshold of 300 m in interstitial lung disease patients with pulmonary hypertension.
See this image and copyright information in PMC

References

    1. Chebib N., Mornex J.F., Traclet J., Philit F., Khouatra C., Zeghmar S., Turquier S., Cottin V. Pulmonary hypertension in chronic lung diseases: Comparison to other pulmonary hypertension groups. Pulm. Circ. 2018;8:2045894018775056. doi: 10.1177/2045894018775056. - DOI - PMC - PubMed
    1. Hoeper M.M., Behr J., Held M., Grunig E., Vizza C.D., Vonk-Noordegraaf A., Lange T.J., Claussen M., Grohe C., Klose H., et al. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. PLoS ONE. 2015;10:e0141911. doi: 10.1371/journal.pone.0141911. - DOI - PMC - PubMed
    1. Gall H., Felix J.F., Schneck F.K., Milger K., Sommer N., Voswinckel R., Franco O.H., Hofman A., Schermuly R.T., Weissmann N., et al. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. J. Heart Lung Transplant. 2017;36:957–967. doi: 10.1016/j.healun.2017.02.016. - DOI - PubMed
    1. Lettieri C.J., Nathan S.D., Barnett S.D., Ahmad S., Shorr A.F. Prevalence and outcomes of pulmonary arterial ypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129:746–752. doi: 10.1378/chest.129.3.746. - DOI - PubMed
    1. Shlobin O.A., Kouranos V., Barnett S.D., Alhamad E.H., Culver D.A., Barney J., Cordova F.C., Carmona E.M., Scholand M.B., Wijsenbeek M., et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: Results from an international registry. Eur. Respir. J. 2020;55 doi: 10.1183/13993003.01747-2019. - DOI - PubMed

LinkOut - more resources